Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Geetha Palaniappan

Internal Medicine Papillion, NE Medical Doctor

NPI 1376638668 CMS profile 198862

611 Fenwick Dr, Papillion, NE 68046

Open in the dashboard

General payments

$285

17 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$93,630 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Geetha Palaniappan of Papillion, NE is reported in the CMS Open Payments database as having received $285 across 17 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $93,630 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 49th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77 3
2024 General $92 6
2022 General $15 1
2021 General $44 3
2020 General $24 2
2019 General $32 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Geetha Palaniappan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Geetha Palaniappan were reported at $77. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Geetha Palaniappan Internal Medicine median Middle half National median
2019 $32 $159 $48–$570 $163
2020 $24 $119 $33–$402 $114
2021 $44 $135 $37–$521 $132
2022 $15 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $92 $154 $47–$537 $164
2025 $77 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $106 5 payments
  2. Pfizer Inc. $32 3 payments
  3. AstraZeneca UK Limited $30 1 payment
  4. Janssen Biotech, Inc. $21 1 payment
  5. Sobi, Inc $17 1 payment
  6. Genentech, Inc. $16 1 payment
  7. Sirtex Medical Inc $15 1 payment
  8. E.R. Squibb & Sons, L.L.C. $15 1 payment
  9. Gilead Sciences, Inc. $12 1 payment
  10. Epizyme, Inc., $12 1 payment
  11. Other $10 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $251 14 payments
  2. Education $34 3 payments
Products named General payments · program years 2019–2025
  1. EPKINLY $75 3 payments
  2. IMBRUVICA Oncology $31 1 payment
  3. IBRANCE $29 2 payments
  4. DARZALEX $21 1 payment
  5. IMBRUVICA Oncology $21 1 payment
  6. Doptelet $17 1 payment
  7. CREON $16 1 payment
  8. Itovebi $16 1 payment
  9. PAXLOVID $15 1 payment
  10. SIR-Spheres Microspheres $15 1 payment
  11. Other $57 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,196

Median for Medical Oncology: 414

Drug cost

$1,119,731

Median for Medical Oncology: $849,427

Branded share of claims

11.7%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 11 $272,043
Jakafi Ruxolitinib Phosphate Brand 12 $210,033
Kisqali Ribociclib Succinate Brand 12 $204,245
Calquence Acalabrutinib Maleate Brand 14 $190,282
Imbruvica Ibrutinib Brand 13 $187,559
Eliquis Apixaban Brand 30 $23,713
Exemestane Generic 99 $13,370
Letrozole Generic 348 $6,829
Anastrozole Generic 299 $4,603
Enoxaparin Sodium Generic 11 $2,318

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 135 billing codes

Paid by Medicare

$2,140,751

Of which drugs: $1,874,749

Medicare patients

665

Average age 75

Services billed

134,102

551 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 71%
Arthritis 50%
Chronic kidney disease 29%
Diabetes 26%
Ischemic heart disease 23%
Depression 21%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 14 8,801 $393,406
Injection, eflapegrastim-xnst, 0.1 mg J1449 Office 11 3,168 $65,887
Injection, ferric carboxymaltose, 1 mg J1439 Office 19 28,500 $24,741
Vaccine for influenza for injection into muscle 90662 Office 11 11 $900
Injection, fosaprepitant, 1 mg J1453 Office 11 7,200 $787
Injection, paclitaxel, 1 mg J9267 Office 13 8,921 $725
Injection, palonosetron hcl, 25 mcg J2469 Office 18 770 $518
Injection, zoledronic acid, 1 mg J3489 Office 14 120 $464
Injection, magnesium sulfate, per 500 mg J3475 Office 11 474 $199
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 34 1,469 $131

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EPKINLY
  • AbbVie, Inc. $44
$44 — —
Doptelet
  • Sobi, Inc $17
$17 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $15
$15 — —
TUKYSA
  • PFIZER INC. $7
$7 — —
IBRANCE
  • PFIZER INC. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record